Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Items 701–800 of 1,025
Duarte, Y., Márquez‐Miranda, V., Miossec, M. J., & González-Nilo, F. D. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1554 · Cited by 90
Song, J., Ma, W., Gu, X., Zhao, L., Jiang, J., Xu, Y., Zhang, L., Zhou, M., & Yang, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1970-8 · Cited by 87
Vrbanac, J., & Slauter, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00003-7 · Cited by 100
Huth, J. R., Song, D., Mendoza, R. R., Black-Schaefer, C. L., Mack, J. C., Dorwin, S. A., Ladror, U. S., Severin, J. M., Walter, K. A., Bartley, D. M., et al. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700319t · Cited by 71
The Evolving Role of Drug Metabolism in Drug Discovery and Development
Yengi, L. G., Leung, L. Y., & Kao, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9217-9 · Cited by 86
“(A) and (B): Reasons for attrition in drug development (196).”
BackgroundYang, W. S., Shimada, K., Delva, D., Patel, M., Ode, E., Skouta, R., & Stockwell, B. R. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200195s · Cited by 76
Drug Development and the FDA's Critical Path Initiative
Woosley, R. L., & Cossman, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100014 · Cited by 82
“Only one in 10 drugs that enter clinical testing receives eventual FDA approval, in spite of millions of dollars spent on preclinical testing.(2) Alarmingly, for drugs in phase III that have shown evidence of effectiveness in phase II, the failure rate has increased to 50%.”
BackgroundSanoh, S., Tayama, Y., Sugihara, K., Kitamura, S., & Ohta, S. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2014.10.009 · Cited by 84
Future of ToxicologyMechanisms of Toxicity and Drug Safety: Where Do We Go from Here?
Stevens, J. L. (2006) · Chemical Research in Toxicology · doi:10.1021/tx060213n · Cited by 74
Gholobova, D., Gérard, M., Decroix, L., Desender, L., Callewaert, N., Annaert, P., & Thorrez, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-30123-3 · Cited by 84
Regan, D. P., Coy, J. W., Chahal, K. K., Chow, L., Kurihara, J. N., Guth, A. M., Kufareva, I., & Dow, S. W. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800619 · Cited by 73
“Although these recent early phase I/II trials of CCR2 inhibitors are promising, approval is far from certain as recent data suggest that only 10% of agents entering clinical cancer trials make it to Food and Drug Administration approval (21, 22).”
BackgroundIntegrated??Pharmacokinetics??and Pharmacodynamics in??Drug??Development
Dingemanse, J., & Appel‐Dingemanse, S. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746090-00001 · Cited by 83
ADME of Biologics—What Have We Learned from Small Molecules?
Prueksaritanont, T., & Tang, C. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9353-6 · Cited by 80
In vitro microscale systems for systematic drug toxicity study
Sung, J. H., & Shuler, M. L. (2009) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-009-0369-y · Cited by 82
“Function is preserved for only a few hours 14 Bioprocess Biosyst Eng (2010) 33:5–19”
BackgroundMethodInfluentialRole of Biotransformation Studies in Minimizing Metabolism-Related Liabilities in Drug Discovery
Shu, Y., Johnson, B. M., & Yang, T. J. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9016-9 · Cited by 75
Leitstruktur‐orientierte Synthese: eine Alternative für die Synthesechemie
Nadin, A. J., Hattotuwagama, C. K., & Churcher, I. (2012) · Angewandte Chemie · doi:10.1002/ange.201105840 · Cited by 75
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review
Vogelbaum, M. A., Krivosheya, D., Borghei-Razavi, H., Sanai, N., Weller, M., Wick, W., Soffietti, R., Reardon, D. A., Aghi, M. K., Galanis, E., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa149 · Cited by 80
Mimicking Human Pathophysiology in Organ‐on‐Chip Devices
Yeşil-Çeliktaş, Ö., Hassan, S., Miri, A. K., Maharjan, S., Al‐kharboosh, R., Quiñones‐Hinojosa, A., & Zhang, Y. S. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800109 · Cited by 81
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm
Walter, R. B., Appelbaum, F. R., Tallman, M. S., Weiss, N. S., Larson, R. A., & Estey, E. H. (2010) · Blood · doi:10.1182/blood-2010-05-285387 · Cited by 77
Bioanalysis in drug discovery and development
Pandey, S., Pandey, P. M., Tiwari, G., & Tıwarı, R. (2010) · Pharmaceutical Methods · doi:10.4103/2229-4708.72223 · Cited by 90
Schultz, L., Zurich, M., Culot, M., Costa, A. D., Landry, C., Bellwon, P., Kristl, T., Hörmann, K., Ruzek, S., Aiche, S., et al. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.05.016 · Cited by 81
“Very high attrition rate (Kola and Landis, 2004) and too few compounds to begin with are the reason for inefficient drug development for neurodegenerative diseases, including Alzheimer’s disease (Cummings et al.”
Stadler, M., Walter, S., Walzl, A., Kramer, N., Unger, C., Scherzer, M., Unterleuthner, D., Hengstschläger, M., Krupitza, G., & Dolznig, H. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.007 · Cited by 82
Muñoz, E., Nováček, V., & Vandenbussche, P.-Y. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbx099 · Cited by 76
“In silico approaches to predict ADRs of candidate drugs are now commonly used to complement costly and time-consuming in vitro methods [7].”
BackgroundGouin, J., MacNeil, S., Switzer, A., Carrese‐Chacra, E., Durif, F., & Knaüper, B. (2020) · Canadian Journal of Public Health · doi:10.17269/s41997-020-00457-5 · Cited by 78
Olson, P., Chu, G. C., Perry, S. R., Nolan-Stevaux, O., & Hanahan, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111079108 · Cited by 73
“However, many drugs that are successful in preclinical trials fail in the clinic (1).”
BackgroundKinetic target-guided synthesis
Hu, X., & Manetsch, R. (2010) · Chemical Society Reviews · doi:10.1039/b904092g · Cited by 80
Bacterial mutagenicity screening in the pharmaceutical industry
Escobar, P. A., Kemper, R. A., Tarca, J. P., Nicolette, J. J., Kenyon, M., Glowienke, S., Sawant, S. G., Christensen, J., Johnson, T. E., McKnight, C. G., et al. (2012) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2012.12.002 · Cited by 78
Microengineered peripheral nerve-on-a-chip for preclinical physiological testing
Huval, R. M., Miller, O. H., Curley, J. L., Fan, Y., Hall, B. J., & Moore, M. J. (2015) · Lab on a Chip · doi:10.1039/c4lc01513d · Cited by 71
Chen, G., Warrack, B. M., Goodenough, A. K., Wei, H., Wang‐Iverson, D. B., & Tymiak, A. A. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.003 · Cited by 73
Bjørnstad, S., Austdal, L. P. E., Roald, B., Glover, J. C., & Paulsen, R. E. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227025 · Cited by 83
“Lack of safety contributes to 30% of failures, whereas lack of efficacy is the other major cause of attrition (Kola and Landis, 2004).”
BackgroundSystematic heterogenization for better reproducibility in animal experimentation
Richter, S. H. (2017) · Lab Animal · doi:10.1038/laban.1330 · Cited by 78
DeltaDelta neural networks for lead optimization of small molecule potency
Jiménez-Luna, J., Pérez-Benito, L., Martínez-Rosell, G., Sciabola, S., Torella, R., Tresadern, G., & De Fabritiis, G. (2019) · Chemical Science · doi:10.1039/c9sc04606b · Cited by 69
Dose Predictions for Drug Design
Maurer, T. S., Smith, D. A., Beaumont, K. C., & Di, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01365 · Cited by 77
The researchers’ view of scientific rigor—survey on the conduct and reporting of in vivo research
Reichlin, T. S., Vogt, L., & Würbel, H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0165999 · Cited by 72
Sirenko, O., Hesley, J., Rusyn, I., & Cromwell, E. F. (2014) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2014.592 · Cited by 73
“Accordingly, there is a high demand for the development of predictive and disease-relevant cell-based assays that can be used for the efficient assessment of chemicals and drug candidates in a high-throughput quantitative screening format.(4,5)”
BackgroundWatt, G. F., Scott-Stevens, P., & Gaohua, L. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.005 · Cited by 70
“pharmaceutical industry there is a strong focus on establishing preclinical PK/PD relationships to aid translation and to reduce drug attrition in later stage clinical development [24,48].”
BackgroundKim, J. J., Ellett, F., Thomas, C. N., Jalali, F., Anderson, R. R., Irimia, D., & Raff, A. B. (2019) · Lab on a Chip · doi:10.1039/c9lc00399a · Cited by 69
Early Implementation of QbD in Biopharmaceutical Development: A Practical Example
Zurdo, J., Arnell, A., Obrezanova, O., Smith, N., Gómez de la Cuesta, R., Gallagher, T. R. A., Michael, R., Stallwood, Y., Ekblad, C., Abrahmsén, L., et al. (2015) · BioMed Research International · doi:10.1155/2015/605427 · Cited by 66
“Here, we show that manufacturing is not only a central component of product success, but also that, by integrating manufacturing and discovery activities in a “holistic” interpretation of QbD methodologies, we could expect to increase the efficiency of the drug discovery process as a whole.”
BackgroundHuman induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies
Jung, Y. W., Hysolli, E., Kim, K., Tanaka, Y., & Park, I. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283518226 · Cited by 85
Gerets, H. H. J., Hanon, É., Cornet, M., Dhalluin, S., Depelchin, O., Canning, M., & Atienzar, F. (2008) · Toxicology in Vitro · doi:10.1016/j.tiv.2008.11.012 · Cited by 72
McCall, R., Miles, M. H., Lascuna, P., Burney, B., Patel, Z., Sidoran, K. J., Sittaramane, V. K., Kocerha, J., Grossie, D. A., Sessler, J. L., et al. (2017) · Chemical Science · doi:10.1039/c7sc02153d · Cited by 77
An analysis of the use of dogs in predicting human toxicology and drug safety
Bailey, J., Thew, M., & Balls, M. (2013) · Alternatives to Laboratory Animals · doi:10.1177/026119291304100504 · Cited by 71
Yamamoto, Y., Välitalo, P. A. J., van den Berg, D., Hartman, R., van den Brink, W., Wong, Y. C., Huntjens, D. R. H., Proost, J. H., Vermeulen, A., Krauwinkel, W. J. J., et al. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2065-3 · Cited by 74
“Central nervous system (CNS) drug development suffers from 91% attrition rate and especially the success rate in phase II is very low (1,2).”
BackgroundUrinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development
van Meer, L., Moerland, M., Cohen, A. F., & Burggraaf, J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12282 · Cited by 71
Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice
Cartwright, M. E., Cohen, S., Fleishaker, J. C., Madani, S., McLeod, J. F., Musser, B., & Williams, S. A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.286 · Cited by 63
Next generation oncology drug development: opportunities and challenges
Gutierrez, M. E., Kummar, S., & Giaccone, G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.38 · Cited by 73
Drug profiling: knowing where it hits
Merino, A., Bronowska, A. K., Jackson, D., & Cahill, D. J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.06.006 · Cited by 77
Bergström, C. A. S. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960303.x · Cited by 78
Systems pathology—taking molecular pathology into a new dimension
Faratian, D., Clyde, R. G., Crawford, J. W., & Harrison, D. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.102 · Cited by 75
Balancing Learning and Overfitting in Genetic Programming with Interleaved Sampling of Training Data
Gonçalves, I., & Silva, S. (2013) · Lecture notes in computer science · doi:10.1007/978-3-642-37207-0_7 · Cited by 71
Filipe, H. A. L., Moreno, M. J., Róg, T., Vattulainen, I., & Loura, L. M. S. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp501622d · Cited by 76
Soluble Salts and Cocrystals of Clotrimazole
Mittapalli, S., Mannava, M. K. C., Khandavilli, U. B. R., Allu, S., & Nangia, A. K. (2015) · Crystal Growth & Design · doi:10.1021/acs.cgd.5b00268 · Cited by 71
Mogil, J. S. (2017) · Lab Animal · doi:10.1038/laban.1223 · Cited by 78
High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model
Conant, G., Lai, B. F. L., Lu, R. X. Z., Korolj, A., Wang, E. Y., & Radisic, M. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9736-2 · Cited by 75
Musuamba, F. T., Manolis, E., Holford, N. H. G., Cheung, S. Y. A., Friberg, L. E., Ogungbenro, K., Posch, M., Yates, J. W. T., Berry, S. M., Thomas, N., et al. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12196 · Cited by 75
Maher, S., Geoghegan, C., & Brayden, D. J. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825375 · Cited by 75
Ungogo, M. A., Ebiloma, G. U., Ichôron, N., Igoli, J. O., de Koning, H. P., & Balogun, E. O. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.617448 · Cited by 81
“…the DDP drastically thins out after each step and stage-from available records only 2.5% of stage-1 compounds make it to stage 2, of which just 2% pass to stage 3, and 5% of the stage-3 candidates may eventually end up getting approved to be in the market (Kola and Landis, 2004; Tonkens, 2005).”
BackgroundInfluentialZebrafish assays as early safety pharmacology screens: Paradigm shift or red herring?
Redfern, W. S., Waldron, G. J., Winter, M. J., Butler, P., Holbrook, M., Wallis, R., & Valentin, J. (2008) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2008.05.006 · Cited by 78
Pohjala, L., Tammela, P., Samanta, S., Yli‐Kauhaluoma, J. T., & Vuorela, P. M. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.12.038 · Cited by 79
“038 successful drug development because toxicity still remains one of the major reasons for failure in the drug development process [1].”
BackgroundZhang, X., Li, C., & Gong, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091874 · Cited by 78
“One of the main underlying causes of such high attrition rate is believed to be a lack of reliable predictive preclinical toxicity studies, particularly in in vivo animal models [73].”
BackgroundCardiotoxicity screening: a review of rapid-throughput in vitro approaches
Li, X., Zhang, R., Zhao, B., Lossin, C., & Cao, Z. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1651-1 · Cited by 77
Hippo pathway and breast cancer stem cells
Maugeri‐Saccà, M., & Maria, R. D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.004 · Cited by 75
Lacombe, O., Videau, O., Chevillon, D., Guyot, A.-C., Contreras, C., Blondel, S., Nicolas, L., Ghettas, A., Bénech, H., Thevenot, E., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1004614 · Cited by 66
Kane, C., & Terracciano, C. M. N. (2017) · Stem Cells · doi:10.1002/stem.2649 · Cited by 64
Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints
Mehta, C. R., Schäfer, H., Daniel, H., & Irle, S. (2014) · Statistics in Medicine · doi:10.1002/sim.6272 · Cited by 69
“Nearly 60% of oncology trials fail in phase 3 testing [1].”
BackgroundLesterhuis, W. J., Rinaldi, C., Jones, A. C., Rozali, E. N., Dick, I. M., Khong, A., Boon, L., Robinson, B. W. S., Nowak, A. K., Bosco, A., et al. (2015) · Scientific Reports · doi:10.1038/srep12298 · Cited by 75
Metabolic Flux Analysis in Systems Biology of Mammalian Cells
Niklas, J., & Heinzle, E. (2011) · Springer eBooks · doi:10.1007/10_2011_99 · Cited by 79
Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies
Greene, N., Aleo, M. D., Louise‐May, S., Price, D. A., & Will, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.129 · Cited by 69
Unraveling the autoimmune translational research process layer by layer
Blumberg, R. S., Dittel, B. N., Hafler, D. A., von Herrath, M., & Nestle, F. O. (2012) · Nature Medicine · doi:10.1038/nm.2632 · Cited by 74
Genomics and transcriptomics in drug discovery
Dopazo, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.003 · Cited by 74
Artamonov, O. S., Slobodyanyuk, E. Y., Volochnyuk, D. M., Komarov, I. V., Tolmachev, A. A., & Mykhailiuk, P. K. (2014) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201402158 · Cited by 69
Szymanska, B., Wilczynska-Kalak, U., Kang, M. H., Liem, N. L. M., Carol, H., Boehm, I., Groepper, D., Reynolds, C. P., Stewart, C. F., & Lock, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033894 · Cited by 69
“The attrition rate of potential anti-cancer drugs entering clinical trial is very high, with one study reporting only 5% of agents gaining US FDA approval in 1991–2000 [10].”
BackgroundA comparison of model choices for the continual reassessment method in phase I cancer trials
Paolettí, X., & Kramar, A. (2009) · Statistics in Medicine · doi:10.1002/sim.3682 · Cited by 69
Schneider, M. R., & Yarden, Y. (2015) · Oncogene · doi:10.1038/onc.2015.372 · Cited by 70
Maximizing the impact of microphysiological systems with in vitro–in vivo translation
Cirit, M., & Stokes, C. L. (2018) · Lab on a Chip · doi:10.1039/c8lc00039e · Cited by 70
Douglass, E. F., Allaway, R. J., Szalai, B., Wang, W., Tian, T., Fernández-Torras, A., Realubit, R., Karan, C., Zheng, S., Pessia, A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100492 · Cited by 68
“This addresses two major reasons for clinical trial failures: lack of safety and efficacy.(43,44) Failure rates may be substantially reduced if compound MoAs could be assessed more accurately and comprehensively (Figures S1A and S1B).”
Ambrosini, Y. M., Park, Y., Jergens, A. E., Shin, W., Min, S., Atherly, T. A., Borcherding, D. C., Jang, J., Allenspach, K., Mochel, J. P., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231423 · Cited by 77
“One primary concern of the human biopharmaceutical industry lies in the fact that most preclinical studies fail to accurately predict the efficacy and safety of drug candidates in human clinical trials [47].”
BackgroundBenz, M., Asperger, A., Hamester, M., Welle, A., Heißler, S., & Levkin, P. A. (2020) · Nature Communications · doi:10.1038/s41467-020-19040-0 · Cited by 73
Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism
Guengerich, F. P. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001173 · Cited by 75
Garner, J. P., Thogerson, C. M., Dufour, B. D., Würbel, H., Murray, J. D., & Mench, J. A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.01.002 · Cited by 63
Regulatory toxicology in the twenty-first century: challenges, perspectives and possible solutions
Tralau, T., Oelgeschläger, M., Gürtler, R., Heinemeyer, G., Herzler, M., Hofer, T. F., Itter, H., Kühl, T., Lange, N., Lorenz, N., et al. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1510-0 · Cited by 72
“%) of registered drugs still fail and 92 % do so because of species-specific toxicity (Astashkina et al. 2012; Knight 2008; Kola 2008; Kola and Landis 2004; Phillips and Crook 2010; Tralau and Luch 2012a).”
BackgroundSnapshot PK: a rapid rodent in vivo preclinical screening approach
Liu, B., Chang, J. J., Gordon, W. P., Isbell, J. J., Zhou, Y., & Tuntland, T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.014 · Cited by 68
Aggregated SOD1 causes selective death of cultured human motor neurons
Benkler, C., O’Neil, A., Slepian, S., Qian, F., Weinreb, P. H., & Rubin, L. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-34759-z · Cited by 71
High-throughput screening for analysis of in vitro toxicity
Schoonen, W. G. E. J., Westerink, W. M. A., & Horbach, G. J. (2009) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-7643-8336-7_14 · Cited by 74
Kinetic deuterium isotope effects in cytochrome P450 oxidation reactions
Guengerich, F. P. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3031 · Cited by 67
Discontinued in 2013: oncology drugs
Williams, R. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.971154 · Cited by 69
“Despite attrition in clinical development having been highlighted for a decade as a fundamental problem for those engaged in drug development [12], there is little evidence in the public domain to suggest that success rates in clinical development are improving and even a recent report suggests that failure rates are…”
BackgroundXu, X., & Zhong, Z. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.63 · Cited by 74
Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening
Baxter, M. A., Rowe, C., Alder, J., Harrison, S., Hanley, K. P., Park, B. K., Kitteringham, N. R., Goldring, C. E., & Hanley, N. A. (2010) · Stem Cell Research · doi:10.1016/j.scr.2010.02.002 · Cited by 66
“One study, published in 2004, analyzed the rate of success for registering products compared to the number of ‘first-in-man’ studies over a decade (19912000) for the 10 largest US and European pharmaceutical companies (Kola and Landis, 2004).”
InfluentialBoosting antibody developability through rational sequence optimization
Seeliger, D., Schulz, P., Litzenburger, T., Spitz, J., Hoerer, S., Blech, M., Enenkel, B., Studts, J. M., Garidel, P., & Karow, A. R. (2015) · mAbs · doi:10.1080/19420862.2015.1017695 · Cited by 66
Ackermann, B., Berna, M., Eckstein, J., Ott, L., & Chaudhary, A. (2008) · Annual Review of Analytical Chemistry · doi:10.1146/annurev.anchem.1.031207.112855 · Cited by 68
RPTEC/TERT1 cells form highly differentiated tubules when cultured in a 3D matrix
Secker, P. F., Luks, L., Schlichenmaier, N., & Dietrich, D. R. (2017) · ALTEX · doi:10.14573/altex.1710181 · Cited by 71
“Currently, chances of a drug candidate entering clinical phase I to be marketed are as low as 7% (Bunnage, 2011) and safety issues or lack of pharmacological efficacy are major reasons (Kola and Landis, 2004) revealed late during development despite extensive nonclinical studies.”
BackgroundRan, R., Wang, H., Hou, F., Liu, Y., Hui, Y., Petrovsky, N., Zhang, F., & Zhao, C. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900015 · Cited by 68
Careers in nanomedicine and drug delivery
Nance, E. A. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.009 · Cited by 68
Requirements for Animal Experiments: Problems and Challenges
Fontana, F., Figueiredo, P., Martins, J. P., & Santos, H. A. (2020) · Small · doi:10.1002/smll.202004182 · Cited by 69
Αbeele, J. V. D., Brouwers, J., Mattheus, R., Tack, J. F., & Augustijns, P. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24647 · Cited by 73
Mathematical modeling in cancer drug discovery
Wang, Z., & Deisboeck, T. S. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.015 · Cited by 72
Model-based drug discovery: implementation and impact
Visser, S. A. G., Aurell, M., Jones, R. D. O., Schuck, V., Egnell, A., Peters, S. A., Brynne, L., Yates, J. W. T., Jansson‐Löfmark, R., Tan, B., et al. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.012 · Cited by 70
Challenges and Opportunities in Developing Novel Drugs for TB
Kaneko, T., Cooper, C. B., & Mdluli, K. E. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.115 · Cited by 74
Pathway Analysis Tools and Toxicogenomics Reference Databases for Risk Assessment
Ganter, B., Zidek, N., Hewitt, P., Müller, D., & Vladimirova, A. (2007) · Pharmacogenomics · doi:10.2217/14622416.9.1.35 · Cited by 66
Developability assessment as an early de-risking tool for biopharmaceutical development
Zurdo, J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.3 · Cited by 75
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.